Join the Oncology Voice Network. Join for Free
MSL “GROWTH”…Within the role and BEYOND
Medical Science Liaison career progression transitioning in pharma skill development mentorship in career growth

MSL “GROWTH”…Within the role and BEYOND


Share This Article


Summary

In this episode, Danielle Day, Senior Medical Director at Sobe North America, joins Tom Caravela to share her journey from academia to the MSL role. Danielle discusses her transition, highlighting her first successful interview and hiring experience, and her progression at AstraZeneca. She emphasizes the significance of being proactive, creative, and engaging internally across functions. The conversation explores career paths, the importance of skill development over job titles, and understanding various roles to manage expectations. Danielle provides insights on transitioning within the industry, gaining diverse experiences, and moving into management, underscoring perseverance and mentorship in career growth.

Danielle Day, Senior Medical Director, Immunology, Rare Disease at Sobi - North America discusses how to grow within the MSL role and beyond.

Danielle shares….

👉 Her career progression and how she GREW her career

👉 The importance of being proactive and collaborative

👉 How to take an out of the box approach

👉 Why you need to ask good questions throughout your career

👉 Looking behind the curtain to see how the sausage is made

Click for Source
Medical Science Liaison, career progression, transitioning in pharma, skill development, mentorship in career growth

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN